Replies to post #173 on Tandem Diabetes Care Inc (TNDM)

[Klinsmann]

R/S is not good for current shareholder, but many don't unterstand that dilution or R/S is a nessesary tool for early stage biotech companies. Guess it's going to dip after RS, than plan to enter